Bovie Medical Appoints Eminent Gynecologic Oncologist to Medical Advisory Board
January 24 2017 - 8:00AM
Business Wire
- Addition of Dr. Chi brings Bovie’s
MAB to five members, who will advance the adoption of
J-Plasma® in new and existing specialties.
Bovie Medical Corporation (“Bovie” or the “Company”) (NYSE:
BVX), a maker of medical devices and supplies and the developer of
J-Plasma®, a patented new surgical product, announced
today the appointment of Dr. Dennis S. Chi, a renowned
gynecologic oncology surgeon, to its Medical Advisory Board.
As Deputy Chief and Head of Ovarian Cancer Surgery at Memorial
Sloan Kettering Cancer Center, Dr. Chi specializes in using the
most advanced minimally invasive surgical techniques to treat
cervical, uterine and ovarian cancer and has received numerous
accolades over his 20-year career.
“Advanced energy technologies such as J-Plasma® hold the promise
of improving outcomes and reducing discomfort and recuperative time
for patients. As an advocate for minimally invasive surgical
techniques and new treatment options for gynecologic oncology, I am
delighted to join Bovie’s Medical Advisory Board,” Dr. Chi
said.
“Dr. Chi’s clinical expertise will be of significant benefit as
J-Plasma®’s adoption continues to gain momentum, both within
existing specialties and across new markets. His appointment
reinforces the enthusiasm top surgeons have for J-Plasma®’s
potential and the caliber of our Medical Advisory Board,” Robert L.
Gershon, Chief Executive Officer of Bovie Medical said.
Dr. Chi has been the principal investigator of several
institutional and multi-center trials, and has published more than
100 papers on ovarian cancer surgery. The addition of Dr. Chi
brings Bovie Medical’s MAB board to five members, representing
specialties which include urology, obstetrics, cardiac surgery,
thoracic surgery, and gynecologic oncology. The MAB has several
clinical studies planned for 2017 to demonstrate the advantages of
J-Plasma® in specific clinical applications.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma®, a patented new
plasma-based surgical product for cutting and coagulation.
J-Plasma® utilizes a helium ionization process to produce a stable,
focused beam of ionized gas that provides surgeons with greater
precision, minimal invasiveness and an absence of conductive
currents through the patient during surgery. Bovie Medical
Corporation is also a leader in the manufacture of a range of
electrosurgical products and technologies, marketed through both
private labels and the Company’s own well-respected brands (Bovie®,
Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also
leverages its expertise through original equipment manufacturing
(OEM) agreements with other medical device manufacturers. For
further information about the Company’s current and new products,
please refer to the Investor Relations section of Bovie Medical
Corporation’s website www.boviemed.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170124005205/en/
Investor Relations:MBS Value PartnersLynn Morgen/Jane
Searle212-750-5800investor.relations@boviemed.com
Bovie (AMEX:BVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bovie (AMEX:BVX)
Historical Stock Chart
From Apr 2023 to Apr 2024